Phenformin

• Description:

  Phenformin (1-phenethylbiguanide) is an orally active antidiabetic and anticancer agent. Phenformin has an incidence of associated lactic acidosis. Phenformin acts through acting AMPK activation and blocking mTOR pathway. Phenformin is also a substrate of P-glycoprotein (P-gp), and an OXPHOS inhibitor. Phenformin induces cancer cell apoptosis[1][2].

• Product Name Alternative:

  Phenethylbiguanide

• UNSPSC:

  12352005

• Hazard Statement:

  H302, H315, H319, H335

• Target:

  AMPK; Apoptosis; Mitochondrial Metabolism

• Type:

  Reference compound

• Related Pathways:

  Apoptosis; Epigenetics; Metabolic Enzyme/Protease; PI3K/Akt/mTOR

• Applications:

  Metabolism-sugar/lipid metabolism

• Field of Research:

  Cancer; Metabolic Disease

• Assay Protocol:

  https://www.medchemexpress.com/phenformin.html

• Purity:

  99.72

• Solubility:

  H2O : 350 mg/mL (ultrasonic)

• Smiles:

  NC(NC(NCCC1=CC=CC=C1)=N)=N

• Molecular Formula:

  C10H15N5

• Molecular Weight:

  205.26

• Precautions:

  H302, H315, H319, H335

• References & Citations:

  [1]García Rubiño ME, et al. Phenformin as an Anticancer Agent: Challenges and Prospects. Int J Mol Sci. 2019 Jul 5;20 (13) :3316.|[2]Yendapally R, et al. A review of phenformin, metformin, and imeglimin. Drug Dev Res. 2020 Jun;81 (4) :390-401.

• Shipping Conditions:

  Room Temperature

• Storage Conditions:

  RT, protect from light

• Scientific Category:

  Reference compound1

• Clinical Information:

  Launched

• Citation 01:

  Int J Biol Macromol. 2025 Aug 21;323 (Pt 1) :147047.|ACS Omega. 2022 Jan 18;7 (4) :3293-3311.|Biomed Pharmacother. 2020 Aug;128:110216.|Cell Rep Med. 2022 Nov 15;3 (11) :100802.|Life Sci. 2019 Jan 15:217:243-250.|Mol Syst Biol. 2023 Jul 11;19 (7) :e11267.|Nat Commun. 2019 Jul 1;10 (1) :2901. |Pharmaceuticals (Basel) . 2024 Sep 19;17 (9) :1234.

• CAS Number:

  [114-86-3]